Hims & Hers' peptide capabilities may be underappreciated, setting up a strong bounce after peptide news. Per @riyadosofian, it is the only telehealth company with a peptide facility and global distribution system. A strong bounce is expected now as the stock holds outside its wedge. x.com  x.com 

Hims & Hers is going higher after its report as growth comes back nicely. The EPS miss was mostly a legal contingency charge, a nothing burger, so shares should rise within weeks if not the next day. x.com  x.com  x.com 

Hims & Hers' latest earnings show a deteriorating business, and hype is not worth much when that happens. x.com  x.com 

Hims & Hers has enormous long-term potential from its brand, personalized platform and recurring model, and that upside heavily outweighs the bear case. Regulation and customer retention are real questions, and they explain why the opportunity exists. x.com 

Hims & Hers looks bullish after its first open-market insider buy in years, because insiders sell for various reasons but buy for only one. Per @himshouse, director David B. Wells, formerly Netflix's CFO, bought 48.4k shares for $1.2 million. A monthly close above $25 is all Hims & Hers needs. x.com 

Hims & Hers is uninvestable without trust in its management team, and there is absolutely no confidence in it. The stock looked overvalued at $60 before its steep fall; as a popular retail stock it could return to $60 or beyond, but distrust of management rules it out. x.com 

Hims & Hers' platform is expanding through regulatory catalysts. An FDA advisory committee voted on adding BPC-157 to the allowed pharmacy compounding list, which could widen its treatment set. Eli Lilly's retatrutide FDA filing slipping to Q1 2027 from the second half of 2026 is also bullish for Hims & Hers. x.com  x.com 

Hims & Hers is at a key support/resistance flip again, and technical risk now points to the upside after months of weakness. With 30% of the float short, the setup could produce a squeeze. x.com 

Hims & Hers is not a $100 stock yet, because growth is slowing and there is no new driver on the scale of GLP-1. Customer acquisition and conversion are slowing and average spend per user is declining, which quarter-over-quarter figures show better than the 40%+ year-over-year narrative. Guidance was narrowed and comparisons get harder. Investing on past strong growth is looking backward. Hims is a great company, but the stock will take time to reach new highs. x.com 

Hims & Hers can reach $700+ within three years because the peptides market will catch many people off guard. x.com